NO20014851L - Behandling av nyrecellekarsinom - Google Patents

Behandling av nyrecellekarsinom

Info

Publication number
NO20014851L
NO20014851L NO20014851A NO20014851A NO20014851L NO 20014851 L NO20014851 L NO 20014851L NO 20014851 A NO20014851 A NO 20014851A NO 20014851 A NO20014851 A NO 20014851A NO 20014851 L NO20014851 L NO 20014851L
Authority
NO
Norway
Prior art keywords
treatment
cell carcinoma
renal cell
effective amount
therapeutically effective
Prior art date
Application number
NO20014851A
Other languages
English (en)
Other versions
NO328983B1 (no
NO20014851D0 (no
Inventor
Esther Helen Rose
Mary Ellen Rybak
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20014851D0 publication Critical patent/NO20014851D0/no
Publication of NO20014851L publication Critical patent/NO20014851L/no
Publication of NO328983B1 publication Critical patent/NO328983B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det beskrives fremgangsmåter for behandling av ikke tidligere behandlede så vel som behandlingserfarne pasienter med RCC for oppnåelse av i det minste en partiell tumorrespons, som omfatter tilførsel av en terapeutisk effektiv mengde av pegylert interferon alfa, f.eks. pegylert interferon alfa-2b, som monoterapi eller i forbindelse med en terapeutisk effektiv mengde av IL-2.
NO20014851A 1999-04-08 2001-10-05 Anvendelse av pegylert interferon alfa for fremstilling av et medikament for behandling av en pasient med renalt cellekarsinom. NO328983B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08
PCT/US2000/009127 WO2000061174A2 (en) 1999-04-08 2000-04-06 Use of pegylated interferon alpha for renal cell carcinoma treatment

Publications (3)

Publication Number Publication Date
NO20014851D0 NO20014851D0 (no) 2001-10-05
NO20014851L true NO20014851L (no) 2001-12-07
NO328983B1 NO328983B1 (no) 2010-07-05

Family

ID=23106761

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014851A NO328983B1 (no) 1999-04-08 2001-10-05 Anvendelse av pegylert interferon alfa for fremstilling av et medikament for behandling av en pasient med renalt cellekarsinom.

Country Status (24)

Country Link
EP (2) EP1535623B1 (no)
JP (2) JP3712914B2 (no)
CN (1) CN1367702A (no)
AR (1) AR029160A1 (no)
AT (2) ATE419002T1 (no)
AU (2) AU777406B2 (no)
BR (1) BR0009644A (no)
CA (1) CA2303752A1 (no)
CO (1) CO5170412A1 (no)
CY (1) CY1108919T1 (no)
DE (2) DE60041291D1 (no)
DK (2) DK1043025T3 (no)
ES (2) ES2239953T3 (no)
HK (2) HK1032533A1 (no)
HU (1) HU230271B1 (no)
MX (1) MXPA00003401A (no)
MY (1) MY155221A (no)
NO (1) NO328983B1 (no)
NZ (1) NZ514629A (no)
PE (1) PE20010026A1 (no)
PT (2) PT1043025E (no)
TW (2) TW200526243A (no)
WO (1) WO2000061174A2 (no)
ZA (1) ZA200108169B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1043025T3 (da) * 1999-04-08 2005-07-04 Schering Corp Behandling af nyrecellekarcinom
CA2648077A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
JP2013523726A (ja) 2010-04-01 2013-06-17 オンコレナ エービー 腎細胞癌の改良された治療
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
WO2018215936A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
PT1066059E (pt) * 1998-03-26 2005-10-31 Schering Corp Formulacoes para proteccao de conjugados de peg-interferao alfa
DK1043025T3 (da) * 1999-04-08 2005-07-04 Schering Corp Behandling af nyrecellekarcinom

Also Published As

Publication number Publication date
DK1535623T3 (da) 2009-04-27
AU2004242454B2 (en) 2007-02-15
TWI310314B (en) 2009-06-01
EP1043025A2 (en) 2000-10-11
CO5170412A1 (es) 2002-06-27
HUP0200781A2 (en) 2002-08-28
JP2001288110A (ja) 2001-10-16
NO328983B1 (no) 2010-07-05
DE60041291D1 (de) 2009-02-12
AU777406B2 (en) 2004-10-14
PE20010026A1 (es) 2001-02-05
WO2000061174A3 (en) 2001-01-25
AU2004242454A1 (en) 2005-01-20
AU4204400A (en) 2000-11-14
BR0009644A (pt) 2002-01-08
DK1043025T3 (da) 2005-07-04
JP2000319196A (ja) 2000-11-21
DE60020442D1 (de) 2005-07-07
HU230271B1 (hu) 2015-11-30
DE60020442T2 (de) 2006-05-04
HUP0200781A3 (en) 2002-09-30
CA2303752A1 (en) 2000-10-08
CN1367702A (zh) 2002-09-04
MXPA00003401A (es) 2002-03-08
EP1043025B1 (en) 2005-06-01
HK1032533A1 (en) 2001-07-27
ZA200108169B (en) 2003-01-06
CY1108919T1 (el) 2014-07-02
JP3712914B2 (ja) 2005-11-02
AR029160A1 (es) 2003-06-18
HK1075417A1 (en) 2005-12-16
PT1043025E (pt) 2005-09-30
NZ514629A (en) 2004-02-27
EP1043025A3 (en) 2000-12-20
ES2319777T3 (es) 2009-05-12
JP4721488B2 (ja) 2011-07-13
EP1535623B1 (en) 2008-12-31
TW200526243A (en) 2005-08-16
MY155221A (en) 2015-09-30
ATE296638T1 (de) 2005-06-15
EP1535623A1 (en) 2005-06-01
NO20014851D0 (no) 2001-10-05
ES2239953T3 (es) 2005-10-16
WO2000061174A2 (en) 2000-10-19
PT1535623E (pt) 2009-03-19
ATE419002T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
CO4940414A1 (es) Terapia de interferones polietilenglicol modificados
DK0911033T4 (da) Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis
PT741577E (pt) Utilizacao do subtipo de interferao alfa 8 na preparacao de medicamentos para tratar infeccoes virais do figado
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
TR200101085T2 (tr) Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
NO20014851L (no) Behandling av nyrecellekarsinom
WO2000004863A3 (en) Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
DK0980205T3 (da) Anvendelse af en kombination af TALL-104 celler med adriamycin eller cisplatin i behandlingen af maligniteter
MY122052A (en) Method of treating tourette''s syndrome
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
CO5180574A1 (es) Micofenolato mofetil en asociacion con peg-inf-a
DE69635630D1 (de) Verwendung eines Leukämie-hemmenden Faktor Antagonisten
MY127276A (en) Cml therapy
Pehamberger Perspectives of pegylated interferon use in dermatological oncology
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
WO2000061175A3 (en) Use of pegylated interferon alpha in melanoma therapy
WO2005102367A3 (en) Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer
BR0316059A (pt) Uso de fosinopril para reduzir eventos cardiovasculares em pacientes de diálise
AU8353601A (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
MX2022009712A (es) Tratamiento de infeccion por coronavirus con interferon lambda.
AU8716001A (en) Treatment of hepatitis c with thymosin and pegylated interferon
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
FR2791894B1 (fr) Utilisation d'interferon beta dans le traitement de la tumeur d'ewing
ECSP003413A (es) Terapia para la leucemia mielocitica cronica

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

MM1K Lapsed by not paying the annual fees